Arbutus Biopharma (ABUS) Non-Current Deferred Tax Liability (2015 - 2019)

Arbutus Biopharma has disclosed Non-Current Deferred Tax Liability across 5 years of filings, most recently posting $12.7 million for Q2 2019.

• Non-Current Deferred Tax Liability for Q2 2019 came in at $12.7 million, down 25.27% year-over-year; the trailing twelve-month figure through Jun 2019 was $12.7 million (down 25.27% YoY), and the FY2018 annual result was $12.7 million, down 25.27% from the prior year.
• Non-Current Deferred Tax Liability came in at $12.7 million for Q2 2019 at Arbutus Biopharma, roughly flat from $12.7 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $156.0 million in Q2 2015 to a low of $12.7 million in Q3 2018.
• The 5-year median for Non-Current Deferred Tax Liability is $41.3 million (2016), against an average of $60.0 million.
• Across the five-year window, Non-Current Deferred Tax Liability tumbled 71.8% in 2016 and retreated 25.27% in 2018, its largest moves.
• Arbutus Biopharma's Non-Current Deferred Tax Liability stood at $146.3 million in 2015, then sank by 71.8% to $41.3 million in 2016, then tumbled by 58.94% to $16.9 million in 2017, then declined by 25.27% to $12.7 million in 2018, then changed by 0.0% to $12.7 million in 2019.
• The last three Non-Current Deferred Tax Liability figures came in at $12.7 million (Q2 2019), $12.7 million (Q1 2019), and $12.7 million (Q4 2018), per Business Quant data.